Annual EBITDA
-$123.48 M
-$4.26 M-3.57%
30 September 2023
Summary:
Enanta Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$123.48 million, with the most recent change of -$4.26 million (-3.57%) on 30 September 2023. During the last 3 years, it has fallen by -$19.23 million (-18.45%). ENTA annual EBITDA is now -197.92% below its all-time high of $126.10 million, reached on 30 September 2015.ENTA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.70 M
+$7.64 M+26.96%
30 June 2024
Summary:
Enanta Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.70 million, with the most recent change of +$7.64 million (+26.96%) on 30 June 2024. Over the past year, it has increased by +$5.00 million (+19.45%). ENTA quarterly EBITDA is now -129.30% below its all-time high of $70.64 million, reached on 31 December 2014.ENTA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$104.68 M
+$11.50 M+9.90%
30 June 2024
Summary:
Enanta Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$104.68 million, with the most recent change of +$11.50 million (+9.90%) on 30 June 2024. Over the past year, it has increased by +$18.80 million (+15.22%). ENTA TTM EBITDA is now -169.97% below its all-time high of $149.60 million, reached on 31 March 2015.ENTA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +19.4% | +15.2% |
| 3 y3 years | -18.4% | +33.1% | -0.4% |
| 5 y5 years | -408.7% | -382.7% | -361.7% |
ENTA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -18.4% | at low | at high | +44.2% | -0.4% | +17.3% |
| 5 y | 5 years | -408.7% | at low | -250.3% | +44.2% | -361.7% | +17.3% |
| alltime | all time | -197.9% | at low | -129.3% | +44.2% | -170.0% | +17.3% |
Enanta Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$20.70 M(-27.0%) | -$104.68 M(-9.9%) |
| Mar 2024 | - | -$28.34 M(-5.4%) | -$116.17 M(-7.0%) |
| Dec 2023 | - | -$29.95 M(+16.5%) | -$124.91 M(+1.2%) |
| Sept 2023 | -$123.48 M(+3.6%) | -$25.70 M(-20.2%) | -$123.48 M(+0.0%) |
| June 2023 | - | -$32.20 M(-13.2%) | -$123.46 M(+0.6%) |
| Mar 2023 | - | -$37.07 M(+30.0%) | -$122.69 M(+3.4%) |
| Dec 2022 | - | -$28.51 M(+11.0%) | -$118.64 M(-0.9%) |
| Sept 2022 | -$119.22 M(+14.4%) | -$25.68 M(-18.3%) | -$119.76 M(-4.2%) |
| June 2022 | - | -$31.43 M(-4.8%) | -$125.01 M(-1.3%) |
| Mar 2022 | - | -$33.02 M(+11.5%) | -$126.61 M(+3.4%) |
| Dec 2021 | - | -$29.63 M(-4.2%) | -$122.45 M(+17.5%) |
| Sept 2021 | -$104.25 M(+174.4%) | -$30.93 M(-6.3%) | -$104.25 M(+13.1%) |
| June 2021 | - | -$33.02 M(+14.4%) | -$92.19 M(+13.7%) |
| Mar 2021 | - | -$28.87 M(+152.6%) | -$81.10 M(+28.3%) |
| Dec 2020 | - | -$11.43 M(-39.5%) | -$63.20 M(+66.3%) |
| Sept 2020 | -$37.99 M(-195.0%) | -$18.87 M(-14.0%) | -$37.99 M(+222.0%) |
| June 2020 | - | -$21.94 M(+100.1%) | -$11.80 M(-179.8%) |
| Mar 2020 | - | -$10.96 M(-179.6%) | $14.78 M(-41.4%) |
| Dec 2019 | - | $13.78 M(+88.1%) | $25.23 M(-36.9%) |
| Sept 2019 | $40.00 M(-56.0%) | $7.32 M(+57.8%) | $40.00 M(-41.0%) |
| June 2019 | - | $4.64 M(-1024.3%) | $67.79 M(-21.6%) |
| Mar 2019 | - | -$502.00 K(-101.8%) | $86.44 M(-17.2%) |
| Dec 2018 | - | $28.54 M(-18.7%) | $104.42 M(+14.9%) |
| Sept 2018 | $90.85 M | $35.11 M(+50.7%) | $90.85 M(-17.9%) |
| June 2018 | - | $23.30 M(+33.3%) | $110.59 M(+48.0%) |
| Mar 2018 | - | $17.47 M(+16.8%) | $74.72 M(+54.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2017 | - | $14.96 M(-72.7%) | $48.27 M(+76.9%) |
| Sept 2017 | $26.75 M(-17.7%) | $54.86 M(-536.2%) | $27.29 M(-186.6%) |
| June 2017 | - | -$12.58 M(+40.1%) | -$31.50 M(+64.8%) |
| Mar 2017 | - | -$8.98 M(+49.2%) | -$19.12 M(+95.3%) |
| Dec 2016 | - | -$6.02 M(+53.3%) | -$9.79 M(-130.1%) |
| Sept 2016 | $32.50 M(-74.2%) | -$3.93 M(+1892.9%) | $32.50 M(-20.4%) |
| June 2016 | - | -$197.00 K(-156.1%) | $40.82 M(-5.5%) |
| Mar 2016 | - | $351.00 K(-99.0%) | $43.17 M(-52.9%) |
| Dec 2015 | - | $36.27 M(+726.5%) | $91.73 M(-27.3%) |
| Sept 2015 | $126.10 M(+542.1%) | $4.39 M(+103.5%) | $126.10 M(+8.0%) |
| June 2015 | - | $2.16 M(-95.6%) | $116.74 M(-22.0%) |
| Mar 2015 | - | $48.91 M(-30.8%) | $149.60 M(+56.5%) |
| Dec 2014 | - | $70.64 M(-1519.7%) | $95.57 M(+386.7%) |
| Sept 2014 | $19.64 M(+98.8%) | -$4.98 M(-114.2%) | $19.64 M(-3.0%) |
| June 2014 | - | $35.02 M(-784.1%) | $20.25 M(-207.5%) |
| Mar 2014 | - | -$5.12 M(-3.2%) | -$18.84 M(+8.2%) |
| Dec 2013 | - | -$5.29 M(+21.3%) | -$17.41 M(-276.3%) |
| Sept 2013 | $9.88 M(-54.2%) | -$4.36 M(+7.2%) | $9.88 M(-3.4%) |
| June 2013 | - | -$4.07 M(+10.2%) | $10.23 M(-5.6%) |
| Mar 2013 | - | -$3.69 M(-116.8%) | $10.83 M(-76.8%) |
| Dec 2012 | - | $22.00 M(-648.3%) | $46.68 M(+116.4%) |
| Sept 2012 | $21.57 M(-20.0%) | -$4.01 M(+15.8%) | $21.57 M(-0.7%) |
| June 2012 | - | -$3.47 M(-110.8%) | $21.72 M(-13.8%) |
| Mar 2012 | - | $32.15 M(-1136.2%) | $25.18 M(-461.3%) |
| Dec 2011 | - | -$3.10 M(-19.8%) | -$6.97 M(+80.2%) |
| Sept 2011 | $26.97 M(+224.9%) | -$3.87 M | -$3.87 M |
| Sept 2010 | $8.30 M | - | - |
FAQ
- What is Enanta Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Enanta Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals TTM EBITDA year-on-year change?
What is Enanta Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ENTA is -$123.48 M
What is the all time high annual EBITDA for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $126.10 M
What is Enanta Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ENTA is -$20.70 M
What is the all time high quarterly EBITDA for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $70.64 M
What is Enanta Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ENTA quarterly earnings before interest, taxes, depreciation & amortization has changed by +$5.00 M (+19.45%)
What is Enanta Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ENTA is -$104.68 M
What is the all time high TTM EBITDA for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $149.60 M
What is Enanta Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ENTA TTM earnings before interest, taxes, depreciation & amortization has changed by +$18.80 M (+15.22%)